XTSESVA
Market cap49mUSD
Dec 24, Last price
0.22CAD
1D
0.00%
1Q
-10.20%
Jan 2017
-26.67%
Name
Sernova Corp
Chart & Performance
Profile
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | 2015‑10 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 41,162 | 25,163 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (41,162) | (25,163) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (629) | 118 | |||||||
Tax Rate | |||||||||
NOPAT | (40,533) | (25,281) | |||||||
Net income | (38,998) 58.92% | (24,539) 249.36% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 20,279 | ||||||||
BB yield | -9.27% | ||||||||
Debt | |||||||||
Debt current | 136 | 140 | |||||||
Long-term debt | 136 | 412 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (19,534) | (49,224) | |||||||
Cash flow | |||||||||
Cash from operating activities | (30,339) | (14,421) | |||||||
CAPEX | (99) | (329) | |||||||
Cash from investing activities | 34,781 | (46,341) | |||||||
Cash from financing activities | 503 | 36,665 | |||||||
FCF | (40,387) | (25,758) | |||||||
Balance | |||||||||
Cash | 19,806 | 49,776 | |||||||
Long term investments | |||||||||
Excess cash | 19,806 | 49,776 | |||||||
Stockholders' equity | (7,179) | 35,115 | |||||||
Invested Capital | 19,830 | 12,770 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 303,332 | 273,593 | |||||||
Price | 0.76 -5.00% | 0.80 -36.00% | |||||||
Market cap | 230,532 5.33% | 218,875 -28.68% | |||||||
EV | 210,999 | 169,650 | |||||||
EBITDA | (40,716) | (24,723) | |||||||
EV/EBITDA | |||||||||
Interest | 32 | 118 | |||||||
Interest/NOPBT |